TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

Also called NCT04951050

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04951050
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04951050. Allocation not applicable; no masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2023-08-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
Acronym
T-P
Condition
Coronary Stenosis
Intervention (Device)
Rapamycin target eluting stent
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04951050
Content hash
d2d09ce7d555392c9d0d811e6e6cac753f284b5ad7641e27dd6cae2870663aa7